Background

Genetic diseases such as Huntington's disease and spinocerebellar ataxia occur when specific DNA sequences in the genome become abnormally long. This is because trinucleotide repeat (TNR) sequences, represented by cytosine-adenine-guanine (CAG), gradually expand during somatic cell division, forming toxic proteins that destroy nerve cells. A pattern in which symptoms progressively worsen as brain cell damage accumulates.

A molecular biological paradox exists here: the DNA mismatch repair (MMM) system, which is supposed to maintain genome stability, is actually the primary driver of these repeat expansions. The complex intended to correct replication errors misinterprets the abnormal loop structures unique to repeat sequences, causing them to expand further.

Researchers have sought therapeutic strategies to block sequence expansion by lowering MMR activity. However, since MMR is a critical defense against mutations, indiscriminate inhibition of the entire complex poses a high risk of cancer. This creates a conflict between maintaining normal function and treating the disease.

To develop a safe therapeutic, it is essential to precisely inhibit only the specific complexes involved in pathological expansion while preserving general single-base correction pathways. However, the lack of analytical technology to precisely measure minute sub-pathways within living cells has been a long-standing challenge.

Key Discovery

Researchers achieved a breakthrough by using prime editing (PE), a next-generation gene editing technology, with an inverse approach. PE is a precise tool that replaces desired sequences without inducing DNA double-strand breaks. The researchers focused on the DNA mismatch intermediates that inevitably occur during the PE process.

By precisely manipulating the PE system in living cells, they induced thousands of programmed DNA mismatches. This allowed them to measure on a large scale how core MMR genes process these artificial mismatch structures.

As a result, sub-pathways within the MMR system that were previously indistinguishable were clearly revealed. A representative achievement is the identification of a loop-directed repair mechanism that specifically recognizes and processes atypical loop structures.

Based on this principle, the researchers constructed an expanded reporter platform that accurately distinguishes the loss of function in different MMR sub-pathways. This is a novel detection system that selectively measures the activity of the MutSβ complex pathway, which drives trinucleotide repeat expansion.

Using this reporter system, the researchers performed high-throughput screening of a library of approximately 72,000 small molecule compounds. The result was the discovery of a new class of compounds that selectively inhibit only the MutSβ-dependent repair pathway.

The discovered small-molecule inhibitors demonstrated efficacy in significantly inhibiting (CAG)n repeat expansion in cellular disease models. The findings are evaluated as securing agents that selectively inhibit disease-causing sequence expansion while preserving general DNA base repair functions.

Significance and Outlook

This study has expanded the application horizon of prime editing into new domains. It represents an achievement in applying PE beyond gene-editing tools to elucidate intracellular molecular mechanisms and establish drug screening platforms.

Analysis suggests this provides a new pathway for deriving therapeutic candidates for trinucleotide repeat neurodegenerative diseases, which were previously classified as incurable. It has opened the practical possibility of developing small-molecule drugs that can selectively control pathological sequence expansion while avoiding the obstacle of systemic mutation risks. This represents a new horizon for patient-specific precision medicine.

Of course, several hurdles remain before commercialization. It must be rigorously verified whether the discovered compound class exhibits the same selectivity in animal models and whether it can cross the blood-brain barrier (BBB) to reach target areas in the central nervous system. Practical challenges such as in vivo drug delivery and ensuring metabolic stability must be addressed.

Furthermore, the potential toxicity of long-term MutSβ inhibition across the genome must be elucidated through additional research. The methodology of precisely dissecting the complex DNA repair network and linking it to drug screening is expected to become a valuable asset for future studies of various genetic diseases.